Cinnamyl-3,4-dihydroxy-α-cyanocinnamate (CDC) is a potent inhibitor of 12/15-Lipoxygenases (LO) with potential for type 1 diabetes mellitus research. In vitro studies demonstrated that CDC partially suppressed dextran transport, while in vivo, it antagonized the effect of high glucose on protein phosphorylation, mitigating endothelial cell barrier destruction in a mouse diabetes mellitus model.
- Potent 12/15-Lipoxygenases (LO) inhibitor
- Potential for research of type 1 diabetes mellitus
- Partially suppressed dextran transport increased by high glucose or 12(S)-HETE in vitro
- Antagonized the effect of high glucose on protein phosphorylation in vivo
- Mitigated endothelial cell barrier destruction in a mouse diabetes mellitus model